Teva gains Leerink Outperform rating as major fund builds $33.8M stake

Leerink Partners initiated coverage of Teva Pharmaceutical Industries with an Outperform rating.

The investment bank set a price target of $45 for the stock.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD disclosed a new position in the company.

The fund purchased 997,617 shares valued at approximately $33.8 million.

Teva now represents the fund's fourth-largest holding.